Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04786925
Other study ID # NUTRIPRECISION
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 16, 2018
Est. completion date December 23, 2020

Study information

Verified date March 2021
Source Clinica Universidad de Navarra, Universidad de Navarra
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The number and proportion of people aged 60 years old and over is increasing worldwide. Ageing is characterized by a progressive loss of physiological integrity, leading to impaired function and increased vulnerability to death. This deterioration is the primary risk factor for major chronic diseases including diabetes, cardiovascular disease, and neurodegenerative disorders. The incidence of chronic conditions frequently rises sharply with age, after long exposure to unhealthful lifestyles involving the consumption of unhealthy diets and physical inactivity. Consequently, integrated dietary strategies and actions are required to promote healthy ageing and target major causes of morbidity and mortality in senior populations. The promising field of precision nutrition is rising as a therapeutic approach that aims to design tailored dietary interventions to prevent and manage chronic diseases. Indeed, precision nutrition approaches contemplate the interindividual heterogeneity caused by genetic/epigenetic dissimilarities, individual facets such as age and gender, the lifestyle and environmental exposome diversity, microbiome variations, and singular behavioral/psychological features. On the other hand, the inclusion of potentially bioactive compounds and functional foods as promoters of healthy aging within personalised dietary patterns could be an effective strategy to delay the aging process and age-related chronic diseases. One of the main limitations of a dietary prescription is the lack of compliance, due to the complexity of the prescription itself and/or the lack of commitment of the individual. The inclusion of digital tools to empower and motivate individuals and to support them in the management of the dietary strategy could overcome this limitation. With this background, the general objective of this investigation is to design precision nutritional strategies based on the inclusion of functional foods and digital tools for preventing age-related chronic diseases in pre-senior and senior populations. Additionally, this study proposes alternative tools for cognitive assessments increasing the accessibility to cognitive assessment tools for this population as well as an innovative digital tool for cognitive stimulation which is personalized, monitored, and evidence-based.


Description:

This study is designed as a 12-week, randomized parallel intervention trial, with two arms: 1) Control group, who follows a control diet based on the current dietary guidelines of the Spanish Society of Community Nutrition (SENC) using the Healthy Eating Plate method (Harvard), and 2) Nutriprecision Group, which were instructed to follow the Nutriprecision diet based on the inclusion of digital tools and functional foods, whose postprandial effects were previously evaluated by randomized, cross-over, double-blind studies in senior subjects in the Centre for Nutrition Research (UNAV) and IMDEA-ALIMENTACIÓN. The incremental area under the curve (iAUC) for glucose and insulin was calculated for all designed foods and was compared with their reference products. Additionally, lipid profile and satiety were measured at fasting and at 15, 30, 45, 60, 90, and 120 min after starting the food intake. In all these studies, the reference and test foods were administered once in random order, with a wash-out period between 7 days and 14 days among assays. This multi-centric study was carried out in the Nutrition Intervention Unit of the Centre for Nutrition Research in the University of Navarra and the Nutritional and Clinical Trials Unit in IMDEA-ALIMENTACIÓN by qualified professionals (nurse, doctor-dietician, dieticians, pharmacists). A total of five visits had been established along with the 12-weeks trial: 1) study information and screening; 2) day 0: start of the intervention; 3) day 28: group session (control group)/follow-up visit (Nutriprecision group); 4) day 56: group session (control group)/follow-up visit (Nutriprecision group) and 5) day 84: end of the intervention. At the start and finish days of the study, participants visited the Nutrition Intervention Unit or the Clinical Trials Unit in a fasting state. Participants were instructed to collect the first-morning urine sample. Additionally, volunteers from the University of Navarra self-collected fecal samples at baseline using OMNIgene.GUT kits from DNA Genotek. Volunteers were also informed of a digital-based procedure for cognitive assessment and other digital tools available depending on the assigned intervention (experimental VS control). Blood samples were drawn by venipuncture after a 12 h overnight fast in a clinical setting. After 10 minutes of rest and having answered the Mini Nutritional Assessment (MNA) and the Mini-Mental State Examination (MMSE) questionnaires, blood pressure was measured. Later, anthropometric measurements and body composition analysis were performed. Global cognitive performance was also assessed by the Guttmann NeuroPersonalTrainer platform. The duration of these visits was approximately 1 hour. On the 28th and 56th study days, participants assigned to the control group attended online group sessions and received intensive education and advice to increase the adherence to the dietary strategy. Sessions consisted of informative talks about the prescribed dietary pattern, food label use, seasonal shopping lists, meal plans and recipes, physical activity and exercise recommendations, sleep habits, etc. Contrary, participants allocated to the Nutriprecision group attended in person visits with the dieticians, to evaluate the adherence to the assigned nutritional treatment. Additionally, anthropometric, body composition, and blood pressure measurements were assessed. Participants were also asked to fill different questionnaires about health status (SF-36 Health Survey), gastrointestinal symptoms (gastrointestinal symptoms rating scale, GSRT), dietary assessment (7-day recall), Mediterranean diet adherence (14-Item Mediterranean Diet Assessment Tool), physical activity (International Physical Activity Questionnaire, IPAQ) and drug therapy modifications. Moreover, the Nutriprecision group were asked to collect a sensory perception questionnaire and a food consumption record of the precision foods administered.


Recruitment information / eligibility

Status Completed
Enrollment 126
Est. completion date December 23, 2020
Est. primary completion date December 23, 2020
Accepts healthy volunteers No
Gender All
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria: - Men and women aged 50-80 years - BMI >27 kg/m2 - One or more of the following risk factors: - Glucose =100 to =125 mg/dL or type 2 diabetes (independently of antidiabetic medication) - Hypertension (systolic blood pressure =140 mmHg or diastolic blood pressure =90 mmHg or under antihypertensive medication) - LDL-cholesterol =160 mg/dL independently of lipid-lowering therapy - HDL-cholesterol =40 mg/dL (men)/=50 mg/dL (women), independently of lipid-lowering therapy - Triglycerides =160 mg/dL independently of lipid-lowering therapy - Waist Circumference ?95 cm (men)/>82 cm (women), independently of lipid-lowering therapy - Sedentary behavior (AHA)* Exclusion Criteria: - Relevant functional or structural digestive abnormalities (malformations, angiodysplasia, active peptic ulcers, chronic inflammatory diseases, or malabsorption) - Endocrine disorders (hyperthyroidism or uncontrolled hypothyroidism) - Undergone surgical interventions with permanent sequelae (gastroduodenostomy) - Pharmacological treatments with immunosuppressants, cytotoxic agents, systemic corticosteroids, or other drugs that could potentially cause hepatic steatosis or alteration of liver tests - Active cancer in the last five years or under therapy - Weight loss =3 kg in the last three months - Instable drug therapy in the last three months - Severe psychiatric disorders - No autonomy - Inability to follow the diet (food allergies, intolerances) - Difficulties to follow scheduled visits - AHA Recommendations for Physical Activity in Adults: at least 150 minutes per week of moderate-intensity aerobic activity or 75 minutes per week of vigorous aerobic activity, or a combination of both, preferably spread throughout the week.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Control diet
Control diet: A Mediterranean conventional diet based on the current dietary guidelines of the Spanish Society of Community Nutrition (SENC). Participants were strongly advised to use the Healthy Eating Plate (Harvard) to structure and prepare the main meals (lunch and dinner). In this way, at least ½ of the plate should be composed of vegetables, ¼ of lean protein, and ¼ of low glycemic index carbohydrates. The diet encourages participants to eat 5 times/day (breakfast, lunch, dinner, and two snacks). Overall, the control diet was based on high consumption of vegetables and fruits, whole grains, healthy fats (olive oil), and healthy proteins (legumes, fish, and lean meat). There was not energy restriction in the control diet.
Nutriprecision diet
Nutriprecision diet: a Mediterranean balanced diet based on the inclusion of precision foods designed according to the particularities of the senior population. The selected precision foods were a) fruit compote, b) smoothie, c) extruded meat product, d) wholemeal bread, e) wholemeal biscuit and f) microwaveable deep-frozen vegetable products. The diet encourages participants to eat 5 times/day with a conventionally balanced distribution of macronutrients (50% of the total caloric value from carbohydrates, 20% from proteins, and 30% from lipids). There was not energy restriction, although the energy requirements of the participants were adjusted to a BMI of 25 kg/m2 to avoid an overestimate of calorie intake. A mobile application designed and developed to provide volunteers with information about follow-up visits, the assigned diet, recommendations, and messages to motivate them during the intervention. A digital tool for cognitive stimulation.

Locations

Country Name City State
Spain Centre for Nutrition Research, University of Navarra Pamplona Navarra

Sponsors (1)

Lead Sponsor Collaborator
Clinica Universidad de Navarra, Universidad de Navarra

Country where clinical trial is conducted

Spain, 

References & Publications (3)

Brooke, JB (1996). SUS - a quick and dirty usability scale. In: Usability Evaluation in Industry, Jordan, P, Thomas, B, Weerdmeester, B, and McLelland, I(eds), Taylor and Francis: London

de Toro-Martín J, Arsenault BJ, Després JP, Vohl MC. Precision Nutrition: A Review of Personalized Nutritional Approaches for the Prevention and Management of Metabolic Syndrome. Nutrients. 2017 Aug 22;9(8). pii: E913. doi: 10.3390/nu9080913. Review. — View Citation

González-Muniesa P, Martínez JA. Precision Nutrition and Metabolic Syndrome Management. Nutrients. 2019 Oct 9;11(10). pii: E2411. doi: 10.3390/nu11102411. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline General Health Status at 3 Months General health score encompassed twelve parameters, on a scale of 0 to 21, with higher scores indicating a worse overall health:
BMI
Waist Circumference
Glycosylated hemoglobin (HbA1C)
Total cholesterol
HDL-cholesterol
LDL-cholesterol
Triglycerides
Uric acid
Systolic Blood Pressure | Diastolic Blood Pressure
Gastrointestinal Health (GSRT)
Cognitive Function
Extra negative point if reducing medication
0 months and 3 months
Secondary Change From Baseline Weight at 3 Months Weight was measured by a digital scale 0 months and 3 months
Secondary Baseline height Height was recorded using a wall-mounted stadiometer (Seca 220, Vogel & Halke, Germany). 0 months
Secondary Change From Baseline Body Mass Index at 3 Months Body mass index was calculated using the standard formula: weight (kg)/height (m)2 0 months and 3 months
Secondary Change From Baseline Fat Mass at 3 Months Fat mass was measured by Bioelectrical impedance analysis (BIA, SC-330, Tanita) 0 months and 3 months
Secondary Change From Baseline Lean Mass at 3 Months Lean mass was measured by Bioelectrical impedance analysis (BIA, SC-330, Tanita) 0 months and 3 months
Secondary Change From Baseline Waist Circumference at 3 Months Waist Circumference was measured by with a tape measure 0 months and 3 months
Secondary Change From Baseline Hip Circumference at 3 Months Hip Circumference was measured by with a tape measure 0 months and 3 months
Secondary Change From Baseline Systolic Blood Pressure at 3 Months Systolic Blood Pressure was measured using an automatic monitor device (Intelli Sense. M6, OMRON Healthcare, Hoofdorp, the Netherlands) 0 months and 3 months
Secondary Change From Baseline Diastolic Blood Pressure at 3 Months Diastolic Blood Pressure was measured using an automatic monitor device (Intelli Sense. M6, OMRON Healthcare, Hoofdorp, the Netherlands) 0 months and 3 months
Secondary Change From Baseline Serum Triglycerides at 3 Months Triglycerides were measured in fasting conditions 0 months and 3 months
Secondary Change From Baseline Serum Total Cholesterol at 3 Months Total cholesterol was measured in fasting conditions 0 months and 3 months
Secondary Change From Baseline Serum LDL-Cholesterol at 3 Months LDL-cholesterol was measured in fasting conditions 0 months and 3 months
Secondary Change From Baseline Serum HDL-Cholesterol at 3 Months HDL-cholesterol was measured in fasting conditions 0 months and 3 months
Secondary Change From Baseline Serum Uric Acid at 3 Months Uric acid was measured in fasting conditions 0 months and 3 months
Secondary Change From Baseline Serum Glucose at 3 Months Glucose was measured in fasting conditions 0 months and 3 months
Secondary Change From Baseline Serum Insulin at 3 Months Insulin was measured in fasting conditions 0 months and 3 months
Secondary Change From Baseline Serum Glycosylated hemoglobin (HbA1C) at 3 Months Glycosylated hemoglobin (HbA1C) was measured in fasting conditions 0 months and 3 months
Secondary Change From Baseline Serum Aspartate Aminotransferase at 3 Months Aspartate aminotransferase was measured in fasting conditions 0 months and 3 months
Secondary Change From Baseline Serum Alanine Aminotransferase at 3 Months Alanine aminotransferase was measured in fasting conditions 0 months and 3 months
Secondary Change From Baseline Serum Gamma-glutamyltransferase at 3 Months Gamma glutamyltransferase was measured in fasting conditions 0 months and 3 months
Secondary Change From Baseline Physical Activity Level at 3 Months Physical activity was measured by the International Physical Activity Questionnaire (IPAQ) 0 months and 3 months
Secondary Change From Baseline Dietary Intake at 3 Months Dietary intake was measured by a 7-day recall 0 months and 3 months
Secondary Change From Baseline Mediterranean Diet Adherence at 3 Months Mediterranean diet adherence was measured by the 14-Item Mediterranean Diet Assessment Tool 0 months and 3 months
Secondary Change From Baseline Health Status at 3 Months Health status was measured by the SF-36 Health Survey 0 months and 3 months
Secondary Change From Baseline Gastrointestinal Symptoms at 3 Months Gastrointestinal symptoms were measured by the gastrointestinal symptoms rating scale, GSRT 0 months and 3 months
Secondary Change From Baseline Sensory Perception of Precision Foods at 3 Months Sensory perception of precision foods was measured by the sensory perception questionnaire 1 month and 3 months
Secondary Food Consumption of the Precision Foods Food consumption of the precision foods was measured by a food consumption record 1 month, 2 months and 3 months
Secondary Change From Baseline Risk of Malnutrition at 3 Months Risk of malnutrition was measured by the Mini Nutritional Assessment (MNA) questionnaire 0 months and 3 months
Secondary Change From Baseline Cognitive Impairment at 3 Months Cognitive impairment was measured by the Mini-Mental State Examination (MMSE) questionnaire 0 months and 3 months
Secondary Change From Baseline Cognitive Function at 3 Months Cognitive function was measured by the Guttmann NeuroPersonalTrainer platform 0 months and 3 months
Secondary Baseline Gut Microbiota Composition Gut Microbiota Composition will be measured using OMNIgene.GUT kits from DNA Genotek 0 months
Secondary Usability of the digital tools Usability will be measured using the System Usability Scale (SUS) 3 months
Secondary Baseline subjective hunger Visual analogue scale rating in a scale from 0 to 100 mm, for the quantification of the perceived hunger before the experimental food intake Baseline
Secondary Postprandial subjective hunger Visual analogue scale rating in a scale from 0 to 100 mm, for the quantification of the perceived hunger measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake Up to 120 minutes
Secondary Baseline subjective fullness Visual analogue scale rating in a scale from 0 to 100 mm for the quantification of the perceived fullness before the experimental food intake Baseline
Secondary Postprandial subjective fullness Visual analogue scale rating in a scale from 0 to 100 mm, for the quantification of the perceived fullness measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake Up to 120 minutes
Secondary Baseline subjective satiety Visual analogue scale rating in a scale from 0 to100 mm for the quantification of the perceived satiety before the experimental food intake. Baseline
Secondary Postprandial subjective satiety Visual analogue scale rating in a scale from 0 to100 mm for the quantification of the perceived satiety measured at 15, 30, 45, 60, 90 and 120 minutes after experimental food intake Up to 120 minutes
Secondary Baseline subjective desire to eat Visual analogue scale rating in a scale from 0 to 100 mm for the quantification of the perceived desire to eat before the experimental food intake at baseline. Baseline
Secondary Postprandial subjective desire to eat Visual analogue scale rating in a scale from 0 to 100 mm for the quantification of the perceived desire to eat measured at 15, 30, 45, 60, 90 and 120 minutes after experimental food intake Up to 120 minutes
Secondary Baseline subjective thirst Visual analogue scale rating in a scale from 0 to 100 mm for the quantification of the perceived thirst before the experimental food intake at baseline Baseline
Secondary Postprandial subjective thirst Visual analogue scale ratings in a scale from 0 to 100 mm for the quantification the perceived thirst measured at 15, 30, 45, 60, 90 and 120 minutes after experimental food intake Up to 120 minutes
Secondary Baseline blood glucose concentration Blood glucose concentration before experimental food intake Baseline
Secondary Baseline blood insulin concentration Blood insulin concentration before experimental food intake Baseline
Secondary Incremental area under the curve (iAUC) for glucose The incremental area under the curve (AUCi) for glucose was calculated via the geometric sums of the areas of the triangles and trapezoids above the fasting glucose concentration over a 2-h period 0,15,30,45,60,90,120
Secondary Incremental area under the curve (iAUC) for insulin The incremental area under the curve (AUCi) for insulin was calculated via the geometric sums of the areas of the triangles and trapezoids above the fasting insulin concentration over a 2-h period 0,15,30,45,60,90,120
Secondary Baseline blood high density lipoprotein cholesterol (HDL) concentration Blood high density lipoprotein cholesterol (HDL) concentration before experimental food intake Baseline
Secondary Baseline blood low density lipoprotein cholesterol (LDL) concentration Blood low density lipoprotein cholesterol (LDL) concentration before experimental food intake Baseline
Secondary Baseline blood triglyceride concentration Blood triglyceride concentration before experimental food intake Baseline
Secondary Postprandial blood glucose concentration Blood glucose concentration measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake Up to 120 minutes
Secondary Postprandial blood insulin concentration Blood insulin concentration measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake Up to 120 minutes
Secondary Postprandial blood total cholesterol concentration Blood total cholesterol concentration measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake Up to 120 minutes
Secondary Postprandial blood high density lipoprotein cholesterol (HDL) concentration Blood high density lipoprotein cholesterol (HDL) concentration measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake Up to 120 minutes
Secondary Postprandial blood low density lipoprotein cholesterol (LDL) concentration Blood low density lipoprotein cholesterol (LDL) concentration measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake Up to 120 minutes
Secondary Postprandial blood triglyceride concentration Blood triglyceride concentration measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake Up to 120 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT06013163 - A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers Phase 1
Active, not recruiting NCT03843424 - Treatment Efforts Addressing Child Weight Management by Unifying Patients, Parents & Providers N/A
Not yet recruiting NCT06360536 - Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women N/A
Not yet recruiting NCT05997576 - A Study of TG103 Injection in Non-diabetic Overweight or Obesity Phase 3
Recruiting NCT04763291 - Cardiovascular and InflammAging Study N/A
Active, not recruiting NCT04399460 - The Effects of Long-term Consumption of Full-fat Dairy Products on Satiety, Body Weight and Glycemic Control N/A
Completed NCT04451824 - Examination of Circumferential Reduction N/A
Completed NCT04110717 - Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control as a Means of Reducing Excess Body Weight N/A
Completed NCT05561855 - T2DM Intensity Lifestyle Intervention N/A
Active, not recruiting NCT04100200 - Berries, Inflammation, and Gut Microbiome N/A
Recruiting NCT06125964 - eMOTION Formative Study N/A
Recruiting NCT06087822 - Multicenter Trial Investigating Performance and Safety of the Medical Device SiPore21® N/A
Active, not recruiting NCT04328233 - Impact of Time-Restricted Eating on Metabolic Homeostasis, Inflammation and Oxidative Stress in Metabolic Syndrome N/A
Completed NCT06091761 - Thread Embedding Acupuncture Combined With Auricular Acupuncture for Overweight and Obesity N/A
Completed NCT04894344 - Education to Decrease in Sodium Intake Evaluated With 24 Hour Urinary Sodium Excretion (RCT) N/A
Completed NCT05713461 - Physical Exercise in Obesity for Health and Quality of Life. N/A
Not yet recruiting NCT06054698 - Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects Phase 2
Not yet recruiting NCT02823912 - Capsaicin Effect on Cytokines Profile in Dyslipidemia Phase 2/Phase 3
Completed NCT05104151 - Efficacy of a Nutritive Bar, in Reduction of Weight, Body Fat and Control of Appetite N/A
Enrolling by invitation NCT06092632 - Efficacy of Pigmented Rice on Reducing Cardiometabolic Risk Factors Among Filipino Adults N/A